Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Research Applications

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor targeting multiple receptor tyrosine kinases, including VEGFRs and HGFR/Met, with low nanomolar IC₅₀ values in biochemical and cellular assays. It effectively suppresses proliferation, migration, and invasion in a range of cancer cell lines, showing cellular MET inhibition at 21–23 nmol/L and in vivo tumor reduction after oral administration at 30 mg/kg. The compound demonstrates multi-pathway blockade, including VEGFR2, VEGFR3, KIT, Flt-3, PDGFRα/β, and Tie-2. Its solubility profile and storage requirements are well-characterized for laboratory workflows. Foretinib is intended for research use only, not for diagnostic or therapeutic purposes (APExBIO; Schwartz 2022).

Biological Rationale

Receptor tyrosine kinases such as VEGFRs and HGFR/Met are critical mediators of tumor angiogenesis, proliferation, and metastasis. Dysregulation of these pathways supports malignant cell survival and migration. Multi-targeted kinase inhibitors provide a strategy to block redundant and compensatory oncogenic signals. Foretinib (GSK1363089) was developed to inhibit a spectrum of kinases implicated in cancer progression, enabling comprehensive pathway suppression (related protocol guide). This article extends previous guides by integrating recent in vitro drug response evaluation principles and robust benchmarking in diverse models.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is a potent, ATP-competitive inhibitor of multiple receptor tyrosine kinases. Its primary targets include MET (HGFR), VEGFR2 (KDR), VEGFR3 (Flt-4), VEGFR1 (Flt-1), KIT, Flt-3, PDGFRα, PDGFRβ, and Tie-2. The compound exhibits IC₅₀ values ranging from 0.4 to 9.6 nmol/L in enzyme assays and inhibits cellular MET phosphorylation at 21–23 nmol/L. Foretinib blocks HGF-induced cell motility, induces G2/M cell cycle arrest, and reduces proliferation. This multikinase blockade disrupts tumor-promoting signaling, leading to decreased cancer cell viability and metastatic potential (Schwartz 2022, p. 30-31). For strategic context, see the mechanistic precision analysis in this article; the present review updates application parameters for translational workflows.

Evidence & Benchmarks

• Foretinib inhibits MET, Ron, KDR (VEGFR2), Flt-1, Flt-4, KIT, Flt-3, PDGFRα/β, and Tie-2 with IC₅₀ values of 0.4–9.6 nmol/L in biochemical kinase assays (APExBIO product data).
• In cellular assays, Foretinib suppresses MET phosphorylation at 21–23 nmol/L, blocking downstream signaling (Schwartz 2022).
• Foretinib inhibits proliferation, migration, and invasion in murine B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cell lines, with nanomolar efficacy (application dossier).
• In vivo, 30 mg/kg oral Foretinib significantly reduces metastatic tumor nodules and tumor weight in ovarian cancer xenograft models (Schwartz 2022, Table 4.2).
• Foretinib is soluble at ≥31.65 mg/mL in DMSO but insoluble in water and ethanol, requiring careful stock preparation and storage at -20°C (APExBIO).

Applications, Limits & Misconceptions

Foretinib is widely used in cancer research for:

• Cell motility inhibition assays to study HGF/Met-driven migration and invasion.
• Tumor growth and metastasis suppression models (in vitro and in vivo).
• Dissecting VEGF receptor signaling pathways in angiogenesis research.
• Investigating multikinase blockade effects in drug combination studies.

Compared to the multidimensional evaluation presented in this review, the present article provides updated boundaries for in vitro and in vivo deployment, clarifying effective dose and solubility constraints.

Common Pitfalls or Misconceptions

• Foretinib is not intended for diagnostic or human therapeutic use; research only.
• Ineffective in aqueous or ethanol solvents due to poor solubility; DMSO is required for stock solutions (APExBIO).
• Prolonged storage at room temperature leads to degradation; maintain at -20°C and use promptly.
• IC₅₀ values are cell- and assay-dependent; direct cross-comparison must control for protocol variability (Schwartz 2022).
• Multi-kinase inhibition may affect off-target pathways; specificity should be confirmed in each model.

Workflow Integration & Parameters

For effective laboratory use, Foretinib should be dissolved in DMSO at concentrations ≥31.65 mg/mL. Prepare aliquots, store at -20°C, and avoid repeated freeze-thaw cycles. Use within recommended timeframes to ensure chemical stability. Standard dosing for in vitro assays ranges from 10–100 nM, adjusted as required by cell line sensitivity. For in vivo xenograft models, oral administration at 30 mg/kg has demonstrated robust antitumor efficacy. Combine with viability and cell death assays as outlined in recent in vitro drug response guidelines (Schwartz 2022). For troubleshooting and protocol optimization, see the actionable strategies detailed in this guide, which the present article expands on by incorporating new solubility and stability data.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, potent multikinase inhibitor for advanced cancer research. Its robust inhibition of VEGFR, HGFR/Met, and associated pathways enables reproducible suppression of tumor cell growth, migration, and metastasis in vitro and in vivo. Proper attention to solubility, storage, and assay selection ensures optimal results. As best practice guidelines for drug response evaluation evolve, Foretinib remains a foundational tool for dissecting oncogenic signaling and testing novel therapeutic hypotheses (Schwartz 2022). For ordering and full specifications, consult the A2974 kit at APExBIO.